Arena Pharmaceuticals, Inc. Listed on Nasdaq National Market System Following Initial Public Offering July 28, 2000--Arena Pharmaceuticals, Inc. (Nasdaq: ARNA - news ) was admitted to the Nasdaq National Market System following its initial public offering of 6 million shares at $18 per share.
Arena prices 6 mln IPO at $18/shr, above range NEW YORK, July 27 (Reuters) - Arena Pharmaceuticals Inc. (Nasdaq: ARNA - news ) sold 6 million shares at $18 per share, above the estimated price range, in its initial public offering on Thursday, according to the lead underwriters.
Arena Pharmaceutcals raises IPO to 6 mln shares WASHINGTON, July 25 (Reuters) - Arena Pharmaceuticals Inc. on Tuesday raised its initial public offering (IPO) to 6 million shares of common stock from 5 million shares. The company, which says it has developed technology that identifies drug
Arena Pharmaceutucals to offer 5 million shares in IPO WASHINGTON, June 22 (Reuters) - Arena Pharmaceuticals Inc., which says it has found a new way of finding new drug candidates more efficiently, on Thursday said it will offer five million shares in a projected price range of $15-$17 per share
Lilly and Arena Form Drug Discovery Alliance INDIANAPOLIS, April 17 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Arena Pharmaceuticals, Inc., announced today that they have entered into an agreement to develop a number of orphan G-protein coupled receptors (GPCRs) as drug screening
Arena Pharmaceuticals Begins Receptor Drug Discovery Collaboration With Fujisawa SAN DIEGO, Jan. 31 /PRNewswire/ -- Arena Pharmaceuticals, Inc. ("Arena"), a privately held biopharmaceutical company, today announced that Arena and Fujisawa Pharmaceutical Co., Ltd., Osaka, Japan ("Fujisawa") have
Neurocrine Biosciences and Arena Pharmaceuticals Announce Receptor Collaboration SAN DIEGO, Sept. 15 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) and Arena Pharmaceuticals, Inc. ("Arena"), a privately held biopharmaceutical company, today announced a collaboration involving the